• 1
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 6171
  • 2
    Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005; 173: 155761
  • 3
    Yossepowitch O, Eggener SE, Bianco FJ Jr et al. Radical prostatectomy for clinically localized, high-risk prostate cancer: critical analysis of risk assessment and methods. J Urol 2007; 178: 4939
  • 4
    Walz J, Joniau S, Chun FK et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010; 107: 76570
  • 5
    Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008; 53: 2539
  • 6
    Van Poppel H, Vekemans K, Da Pozzo L et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006; 42: 10627
  • 7
    Bahler CD, Foster RS, Bihrle R et al. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer. BJU Int 2009; 105: 13726
  • 8
    Soulié M, Rozet F, Hennquin C, Salomon L. Membres du Sous-Comité Prostate du CCAFU. Cancer Radiother 2010; 14: 4939
  • 9
    Koupparis AJ, Grummet JP, Hurtado-Coll A et al. Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Can Urol Assoc J 2011; 1: 16
  • 10
    Gontero P, Spahn M, Tombal B et al. Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int 2011; 108: 1093100
  • 11
    Zwergel U, Suttmann H, Schroeder T et al. Outcome of prostate cancer patients with initial PSA >20 ng/ml undergoing radical prostatectomy. Eur Urol 2007; 52: 105866
  • 12
    Brandli DW, Koch MO, Foster RS, Bihrle R, Gardner TA. Biochemical disease-free survival in patients with a high prostate-specific antigen level (20–100 ng/ml) and clinically localized prostate cancer after radical prostatectomy. BJU Int 2003; 92: 1922
  • 13
    Inman BA, Davies JD, Rangel LJ et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level >50 ng/ml. Cancer 2008; 113: 154451
  • 14
    Gontero P, Joniau S, van Poppel H. Radical prostatectomy for PSA >100 ng/ml prostate cancer. Eur Urol 2008; 54: 9578
  • 15
    Da Pozzo L, Cozzarini C, Briganti A et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009; 55: 100311
  • 16
    Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer – doses treatment of the primary tumor matter? J Urol 2006; 176: 12928
  • 17
    Chade DC, Shariat SF, Cronin AM et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011; 60: 20510
  • 18
    Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic variables, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010; 57: 43745
  • 19
    Sanderson KM, Penson DF, Groshen S, Stein JP, Lieskovsky G, Skinner DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006; 176: 202532
  • 20
    Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173: 115660
  • 21
    Bianco FJ, Scardino PT, Stephenson AJ, DiBlasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 44853
  • 22
    Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004; 172: 223943
  • 23
    Gheiler EL, Tefilli MV, Tiguert R et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998; 51: 78995
  • 24
    Ahallal Y, Shariat SF, Chade DC et al. Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. BJU Int 2011; 108: 7248
  • 25
    Nunez-Mora C, Garcia-Mediero JM, Cabrera-Castillo PM. Radical laparoscopic salvage prostatectomy: medium-term functional and oncological results. J Endourol 2009; 23: 13015
  • 26
    Stolzenburg JU, Bynens B, Do M, Rabenalt R, Katsakiori PF, Liatsikos E. Salvage laparoscopic extraperitoneal radical prostatectomy after failed high-intensity focused ultrasound and radiotherapy for localized prostate cancer. Urology 2007; 70: 95660
  • 27
    Eandi JA, Link BA, Nelson RA et al. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J Urol 2010; 183: 1337
  • 28
    Boris PS, Bhandari A, Krane LS, Eun D, Kaul S, Peabody JO. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU Int 2008; 103: 9526
  • 29
    Kaouk JH, Hafron J, Goel R, Haber GP, Jones JS. Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results. BJU Int 2008; 102: 936
  • 30
    Scattoni V, Picchio M, Suardi N et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 4239
  • 31
    Winter A, Uphoff J, Henke RP, Wawroschek F. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010; 84: 41823
  • 32
    Rinnab L, Mottaghy FM, Simon J et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008; 81: 1917
  • 33
    Galfano A, Novara G. Methodological bases for systematic reviews. J Androl 2008; 15: 19
  • 34
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 216372
  • 35
    Pound CRPA, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 1997; 24: 395406
  • 36
    Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 134851
  • 37
    Messing EM, Manola J, Yao J et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 4729
  • 38
    Gallina A, Jeldres C, Chun FKH et al. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/ml. Eur Urol 2007; 52: 137480
  • 39
    Spahn M, Joniau S, Gontero P et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010; 58: 17
  • 40
    Schröder FH, Kurth KH, Fosså SD et al. Members of the European organisation for the research and treatment of cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European organisation for the research and treatment of cancer 30846–a phase III study. J Urol 2004; 172: 9237
  • 41
    Cheng L, Zincke H, Lute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 6673
  • 42
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy: is there a chance of cure? J Urol 2003; 169: 84954
  • 43
    Engel J, Bastian PJ, Baur H et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010; 57: 75461
  • 44
    Briganti A, Karnes JR, Da Pozzo LF et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 26170
  • 45
    Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characterized of the primary tumor and its lymph node metastases. Prostate 2009; 69: 35262
  • 46
    Canby-Hangino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep 2005; 6: 1839
  • 47
    Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 1982; 127: 123842
  • 48
    Swanson GP, Riggs M, Earle J. Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation. J Urol 2004; 172: 5258
  • 49
    Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002; 168: 100812
  • 50
    Budiharto T, Joniau S, Lerut E et al. Prospective evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 12530
  • 51
    Suardi N, Briganti A, Tutolo M et al. The role of salvage lymph node dissection in patients with [11C]Choline PET/CT scan detected nodal recurrence of prostate cancer after radical prostatectomy. Eur Urol Suppl 2010; 9: 812
  • 52
    Suardi N, Briganti A, Salonia A, Rigatti P. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. Curr Opin Urol 2011; 21: 23740
  • 53
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 17381
  • 54
    Abramowitz MC, Li T, Buyyounouski MK et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008; 112: 5560
  • 55
    Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15: 2308
  • 56
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 35567
  • 57
    Schilling D, Schlemmer HP, Wagner PH et al. Histological verification of 11C-choline positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008; 102: 44651
  • 58
    Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010; 184: 13642
  • 59
    Stephenson AJ, Eastham JA. Role of salvage prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23: 8198203
  • 60
    Finley DS, Pouliot F, Miller DC, Belldegrun AS. Primary and salvage cryotherapy for prostate cancer. Urol Clin North Am 2010; 37: 6782
  • 61
    Pisters LL, Leibovici D, Blute M et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182: 51725
  • 62
    Gontero P, Joniau S, Spahn M. Feasibility Study on the Use of Debulking Surgery in Hormone Refractory Prostate Cancer (HRPC) without Evidence of Systemic Disease Following Previous Radiotherapy. Trial Protocol N° 00039866. Turin: A.O.U. S.Giovanni Battista, 2009